Member Info for Helen3

IMO, will back to at least 190 soon

https://www.eurekalert.org/news-releases/942698

POST-ACUTE SEQUELAE OF SARS-COV-2 IN NON-HOSPITALIZED ACTIV-2 TRIAL PARTICIPANTS (ACTG 5401/ACTIV-2; Poster Presentation: Monday, February 14 2022, 4:00 PM – 5:30 PM EST) Teresa H. Evering, et al.

Is there a link for us to watch?
4:00 PM EST = 9pm UK time

Let's not forget Polygon 18% now.
Think the SP will go up tomorrow.

Correction:
The Placebo group Hospitalization/death 1st part 14.06%, 2nd part only 4.66%.
The Placebo group Hospitalization/death 2nd part dropped 66.86%, not 9.4%.

very dodgy, 50% vs -32.51%

https://i.redd.it/eh6f4ntjg9281.png --- This is the excel file I made

I just did some calculation of the results from MOVe-OUT Study of Molnupiravir, they just say the first 762 participants efficacy is 50%, and the whole study 1433 participants efficacy is 30%.
I wanted to see what is the second half (646 participants) of the study efficacy,
hxxps://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/

So the the second half (646 participants) the efficacy is -32.51%.

15 Hospitalization/death from Placebo group,
20 Hospitalization/death from Molnupiravir group

Hospitalization/death 15/322 Placebo, 20/324 Molnupiravir

i.redd.it/eh6f4ntjg9281.png --- This is the excel file I made

I might be wrong, if anyone have time please double check for me, the News release is here
www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/

One last thing, the reason why the result is so difference is not because of Molnupiravir, they actually did better on the second part of the trial, Hospitalization/death rate 1st part 7.27%, 2nd part 6.17%,
the reason is the Placebo group Hospitalization/death rate 1st part 14.06%, 2nd part only 4.66%.

The Placebo group Hospitalization/death rate on the 2nd part dropped 9.4%, meaning Placebo group 1st part has more than 3 times more Hospitalization/death than 2nd part of the trial.

I think you all might be wrong about the webcast tomorrow 1pm is for analysts only.
In the RNS, "A webcast and Q&A session for analysts will be hosted by Synairgen's management team at 13:00 BST on 30 September 2021."
I think what it meant was there will be a webcast and in the webcast there will be a Q&A session for analysts only.
I just registered to watch the webcast here. https://www.lsegissuerservices.com/spark/Synairgen/events/28f37f03-c7dd-4071-b047-66b191931742
I might be wrong, will find out tomorrow.

Thanks Matterhorn.

Synairgen knows they need to have the trial done ASAP,
and they are trying their best to make it happen,

https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ2

Camostat mesilate
This study has closed.

Good Morning Everyone,

Link to listen to 09:00 AGM.

https://www.lsegissuerservices.com/spark/Synairgen/events/1cd87eb6-5e01-4e1a-b3bd-f8288bbb6b5b

Recruitment finished - 11/05/2020,
Not 11/05/2021
I think it's the P2 trial.

could cause more suffering than in January, oh no :(

https://twitter.com/bbclaurak/status/1392442675098443779

PM warns pandemic isn't over, and threat of new variants, which could be resistant to vaccines, could cause more suffering than in January, also warns there may be an autumn-winter surge in any case this year.

Justification for not starting inquiry yet is that it will take up huge effort including from those still playing big roles, govt medics and scientists -interesting, if it is a truly wide ranging inquiry, puts likely publication after the next general election.

PM also announces a Commission on Commemoration, to work out how to remember the lives lost

are you sure this is the correct video???

Why Covid Patients Could Face A Lifetime Of Money Problems
https://www.youtube.com/watch?v=55e8pKVWWlI

https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, coordinated by the Foundation for the National Institutes of Health (FNIH). ACTIV involves a collaboration among government and industry partners, including FDA, to prioritize vaccine and therapeutic candidates, streamline clinical trials, and rapidly expand the clinical research resources focused on developing therapies for the COVID-19 pandemic. Among other things, ACTIV government and industry partners provide subject matter expertise and/or funding to identify, prioritize and facilitate the entry of some of the most promising candidates into clinical trials.

CTAP plays an important role in these efforts by providing FDA subject matter expertise for ACTIV initiatives, including for clinical trial design and conduct and relevant FDA regulatory standards for therapeutics. Under the CTAP program, FDA can better ensure that critical focus is placed on reviewing those therapies prioritized by the ACTIV partnership. The involvement of FDA in the ACTIV partnership will also help ensure these reviews are more efficient, particularly in evaluating proposed pre-clinical and clinical studies that received ACTIV input. This more comprehensive and cooperative approach involving key partners can help ensure that safe and effective therapies for COVID are available more quickly for patients. However, it should be noted that FDA’s regulatory functions are distinct from its contribution of technical advice to other US government programs. The FDA will evaluate each product submitted for authorization or approval based on the applicable legal and regulatory requirements and on the bases of the best available scientific and clinical evidence.

New one
ACTIV-2 clinical trial protocol

Fnih
https://fnih.org/sites/default/files/final/pdf/Protocol%20ACTIV-2-A5401%20Version%204%20dated%2031March2021.pdf

https://youtu.be/-6UUKBD62gk